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ABSTRACT 
 
AIMS: Over half of infants exposed to opioids in utero develop neonatal 
abstinence syndrome (NAS) of severity to require pharmacologic therapy.  
Current treatments are associated with prolonged hospitalization.  We sought to 
optimize the dose of sublingual buprenorphine in the treatment of NAS. 
 
DESIGN: Randomized, phase 1, open-label, active-control clinical trial comparing 
sublingual buprenorphine to oral morphine. 
 
SETTING: Large, urban, tertiary care hospital. 
 
PARTICIPANTS: Twenty-four term infants with signs and symptoms of NAS. 
 
MEASUREMENTS: Outcomes were neonatal safety, length of treatment, and 
length of hospitalization. 
 
FINDINGS: Sublingual buprenorphine was safe and effective.  Infants treated 
with buprenorphine had a 23-day length of treatment compared to 38 days for 
those treated with morphine (p=0.01), representing a 40% reduction.  Length of 
stay in the buprenorphine group was reduced 24%, from 42 to 32 days (p=0.05). 
 
CONCLUSIONS: Sublingual buprenorphine was safe in NAS, with a substantial 
efficacy advantage over standard of care therapy with oral morphine.  
 
INTRODUCTION 
 
Infants born to mothers receiving methadone maintenance often develop 
withdrawal symptoms in a complex known as the neonatal abstinence syndrome 
(NAS).  NAS is characterized by signs and symptoms of CNS hyperirritability, 
gastrointestinal dysfunction, respiratory distress, and autonomic symptoms. (1)  
Common symptoms in order of frequency include tremors, high-pitched cry, 
sneezing, increased muscle tone, regurgitation and vomiting, poor sleep, loose 
stools, sweating, excoriation, mottling, nasal stuffiness, low-grade fever, and 
tachypnea.  NAS reflects a spectrum of disease, and those with milder symptoms 
respond well to supportive treatments.(2)  NAS symptoms severe enough to 
require pharmacologic treatment occur in 55-94% of infants born to opioid-
dependent mothers. (1) 
 
The optimal pharmacologic regimen for NAS has not been established, as 
reflected in the considerable heterogeneity in the diagnosis (3) and treatment of 
NAS among different institutions. (4,5) Treatments employed have included 
opioids, anticonvulsants, benzodiazepines, alpha 2 adrenergic antagonists, 
chloral hydrate, and the phenothiazine antipsychotic agent chlorpromazine.  
Cochrane reviews, (6,7) the American Academy of Pediatrics, (1) and expert 
review (8,9) identify opioid replacement as the ideal treatment for the withdrawal 
symptoms associated with in utero exposure to opiates.  Morphine is the most 
commonly used agent, and is associated with treatment duration of 8-79 days, 
(10-15) almost always in an inpatient setting.  The use of outpatient treatment in 
highly selected patients has been reported to be associated with shorter inpatient 
stays, but longer total duration of therapy. (16) 
 
Buprenorphine is a long-acting partial mu opioid receptor agonist used in 
the treatment of adult abstinence therapy.  It has the advantage of decreased 
abuse potential and less respiratory depression than other opioid agonists.  We 
have previously reported the first use of sublingual buprenorphine in NAS at a 
dose of 13.2 mcg/kg/day in three divided doses. (17) Though designed as a 
phase 1 safety study, the investigation suggested reduction in lengths of 
treatment and inpatient hospitalization of approximately 30%.  A higher incidence 
of phenobarbital adjunctive therapy in the buprenorphine group led us to optimize 
dose parameters.  We report here on a second cohort of 24 patients treated with 
this revised dose schema. 
 
METHODS 
 
Study Design 
This was a single site, randomized, open label trial. (Figure 1)  Neonates 
were randomized to treatment with either sublingual buprenorphine or oral 
morphine in a 1:1 ratio.  NAS was graded using the MOTHER NAS score, which 
is the standard instrument used in the multicenter NIH funded MOTHER study 
(ClinTrials.gov ID NCT00271219) of buprenorphine in pregnancy. (18) It is also 
the standard instrument at TJUH.  The MOTHER NAS score (hereafter “NAS 
score”) is based upon the Finnegan score, (19) modifications of which are the 
most commonly used to monitor NAS. (5,20) Initiation of treatment was based on 
any consecutive 3 scores adding up to ≥ 24.  Inclusion criteria included ≥ 37 
weeks gestation, exposure to opioids in utero, and demonstration of signs and 
symptoms of NAS requiring treatment.  Exclusion criteria were major congenital 
malformations and/or intrauterine growth retardation, (21) medical illness 
requiring intensification of medical therapy, concomitant maternal 
benzodiazepine or severe alcohol abuse, maternal use of alcohol or of 
benzodiazepines in the 30 days prior to enrollment (as determined by self-report 
or intake urine drug screen), concomitant neonatal use of cytochrome P450 3A 
inhibitors or inducers prior to treatment, seizure activity or other neurologic 
abnormality, breast feeding or inability of mother to give informed consent due to 
co-morbid psychiatric diagnosis.  The study was approved by the Institutional 
Review Board of Thomas Jefferson University.  Computer-generated 
randomization was performed by the hospital Investigational Drug Service. 
 
Study Treatments 
Patients randomized to sublingual buprenorphine initially received 15.9 
mcg/kg/day in 3 divided doses.  Buprenorphine solution was prepared by mixing 
buprenorphine for injection (Buprenex, Reckitt Benckiser) to a final concentration 
of 0.075 mg/mL in 100% ethanol USP (30% of total volume) and simple syrup 
USP (85 gm sucrose/100 ml).  The solution was administered under the tongue 
followed by insertion of a pacifier to reduce swallowing.  Dose escalation was a 
25% increase for NAS scale scores ≥24 total on 3 measures or a single score of 
≥12.  Patients with inadequate control could be administered a rescue dose of 
50% of the previous dose, after which the subsequent dose would be advanced 
25%.  After at least 3 days of dose stabilization, patients could begin weaning for 
scores < 8.  Weaning was at intervals of 10%.  Cessation of dosing occurred 
when buprenorphine was within 10% of the initial dose.  All dose calculations 
were based upon birth weight.  If NAS was not controlled with maximally 
specified dose of 60 mcg/kg/day, patients were administered phenobarbital 20 
mg/kg load followed by 2.5 mg/kg twice a day for at least 2 days.  Phenobarbital 
was weaned prior to reduction of the opioid.  When NAS scores were reliably <8, 
the daily dose of phenobarbital was reduced by 50%, followed by complete 
cessation. 
 
Standard of care treatment at Thomas Jefferson University Hospital 
consisted of an initial dose of morphine 0.4 mg/kg/day in 6 divided doses with 
dose escalation of 10%/day for NAS scale scores ≥24 total on 3 measures or a 
single score of ≥12.  All dose calculations were based upon daily weight.  
Adjunctive treatment with phenobarbital was initiated when the dose of morphine 
reached 1 mg/kg/day.  Weaning from the phenobarbital was the same in both the 
buprenorphine and morphine groups.  Infants were weaned with 10% dose 
reduction every 24 hours in morphine as tolerated until 0.15 mg/kg/day was 
reached.  All patients in the trial were observed for at least two days following the 
cessation of dosing. 
 
Statistics 
This was a follow up pilot study to optimize the dose of sublingual 
buprenorphine in neonates.  Therefore, sample size was not based upon a 
formal power calculation.  Group comparisons for continuous variables were 
made using the Mann-Whitney U test.  Statistical analysis was completed with 
JMP 5.1.2, (SAS Institute Inc.)  Analysis was performed on an intention to treat 
basis. 
 
RESULTS 
Twenty-four infants were enrolled between March 2008 and January 2010.  
Patient characteristics are presented in Table 1. 
 
Safety 
A list of all adverse events observed in the trial is presented in Table 2.  
There was one serious adverse event in a patient randomized to buprenorphine.  
This infant randomized to buprenorphine had adverse events of CMV infection, 
prolonged reflux/poor feeding, elevated transaminases, aminoaciduria, and 
paronychia of a finger.  Poor feeding and enteral hypomotility was initially thought 
to be part of NAS, but lack of resolution on buprenorphine and phenobarbital, 
and indeed no worsening when these drugs were removed led to further medical 
evaluation.  CMV was noted in urine, and a lack of cerebral calcifications or 
microcephaly at birth suggest a late in utero or possibly nosocomial infection.  
Length of buprenorphine treatment was 45 days and length of stay was 98 days.  
On the last day of buprenorphine weaning, alanine transaminase (ALT) was 
noted to be 30x the upper limit of normal (ULN), while aspartate transaminase 
(AST) was noted to be 20x ULN.  These values waxed and waned over the 
remainder of the hospitalization, and remained elevated 6 weeks following the 
cessation of buprenorphine.  Bilirubin was never elevated.  The DSMB reviewed 
the case and came to the unanimous judgment that buprenorphine was not 
responsible for the clinical course of the infant, but did endorse our suggestion to 
monitor liver function for future enrollees.  Liver function testing pre-dose, and at 
7 and 21 days post randomization was normal in 6 subsequent patients (three in 
each treatment arm). 
 
Efficacy 
Infants treated with buprenorphine had a 23-day length of treatment 
compared to 38 days for those treated with morphine (p=0.01). (Table 3 and 
Figure 2)  This represents a 40% reduction.  Length of stay in the buprenorphine 
group was reduced 24%, from 42 to 32 days (p=0.05).  Three infants treated with 
buprenorphine required phenobarbital compared to one infant treated with 
morphine. 
 
DISCUSSION 
This study builds upon our prior report describing the use of 
buprenorphine in the treatment of opioid NAS.  The goal of the current 
investigation was to optimize buprenorphine dosing by increasing the 1) initial 
dose, 2) rate of dose up-titration, and 3) maximum daily dose.  An increase in 
stock drug concentration was used to maintain manageable drug volume for 
administration.  Sublingual buprenorphine continued to maintain safety at these 
higher doses.  In addition, there was continued advantage over morphine in 
length of treatment and length of stay, which was now statistically significant.  It 
is arguable that many signs and symptoms observed in the infant with CMV 
infection did not reflect severity of NAS but instead were manifestations of the 
multiorgan viral process.  Data from this infant was included in the primary 
analysis.  However, removal of this infant causes the length of treatment to drop 
from 23 to 21 days, and length of stay to drop from 32 to 26.  
Three patients in the buprenorphine group required the use of adjunctive 
phenobarbital compared to one patient in the morphine group.  Phenobarbital is 
often used as a rescue therapy when maximum opioid replacement therapy dose 
is reached without adequate resolution of symptoms.  It has also been used as 
an initial adjunct in combination therapy with an opioid (12) or as initial 
monotherapy. (22)  Morphine and buprenorphine employ different up-titration 
rates and number of up-titrations until maximum dose is reached (6 for 
buprenorphine and 9 for morphine).  Thus, the need for adjunctive phenobarbital 
is not necessarily a surrogate of “treatment failure” in infants with a more severe 
withdrawal symptom complex.  Phenobarbital arguably has a therapeutic index 
similar to that of opioid treatment in this patient population.  It is also not clear 
where on the dose response curve the present maximum buprenorphine dose 
lies.  Thus it is possible as a partial agonist, buprenorphine may not be able to 
induce the dense signal generation at the mu opioid receptor obtained with 
morphine.  Alternatively, it could be hypothesized that a higher maximum dose of 
buprenorphine could reduce the frequency with which adjunctive phenobarbital 
would need to be used.  However, as there are no definitive adverse events 
associated with short-term exposure to phenobarbital, it is possible that a short 
course of phenobarbital may be a useful adjunct to reduce total duration of 
treatment in children with more severe withdrawal symptoms. 
A mechanistic basis for the improvement of buprenorphine over morphine 
is not immediately clear.  The longer duration of action and residence at the mu 
opioid receptor of buprenorphine relative to morphine may reduce the sudden 
shifts in receptor agonism and withdrawal symptoms.  A more prolonged 
persistence of drug effect following cessation likely reduces symptoms.  Two 
features of buprenorphine dosing compared to morphine also merit noting.  
Buprenorphine has a more rapid up-titration of dose compared to morphine, 
which may allow a quicker attainment of symptom control.  Though both 
regimens employ a 10% weaning schedule, buprenorphine is stopped when a 
dose within 10% of the starting dose.  In contrast, the initial morphine dose is 0.4 
mg/kg/day, while cessation of dosing takes place only after drug has been 
weaned to 0.15 mg/kg/day.  Finally, the buprenorphine group dosing was based 
upon birth weight, while the morphine group was dosed according to daily weight.  
This difference serves to decrease a relative dose of buprenorphine as the infant 
grows. 
This study was of an open label, randomized, design with primary goals of 
demonstrating safety and feasibility of sublingual buprenorphine.  It is possible 
that there was occult bias in the scoring of infants by the nurse evaluators, 
despite the use of structured training sessions.  A double blind, double dummy 
study would be required to fully evaluate any differential efficacy of 
buprenorphine over morphine.  Another limitation is that the study excluded 
infants with benzodiazepine exposure and preterm infants.  These exclusions 
serve to limit the generalizability of results.  Infants with in utero benzodiazepine 
exposure have a longer length of stay and treatment compared to those without. 
(15,23-25)  These infants represent a group in whom research should be 
directed.  Premature infants typically have less severe NAS, (26) but 
buprenorphine does not have an established safety record in this population.  
Finally, while the length of treatment and length of stay noted is this study is 
consistent with observational data at Thomas Jefferson University Hospital 
between 2000-2006, (15) it is longer than has been noted at other institutions. 
(10,13,27,28)  It is not clear if the magnitude of advantage over standard therapy 
would be maintained at institutions with a shorter length of stay. 
In conclusion, buprenorphine at an optimized dose schema has been 
demonstrated to be safe and efficacious in the treatment of NAS.  While 
indications of a therapeutic advantage over morphine again have been 
demonstrated, these need to be verified in a double blind clinical trial.  
Additionally, the unique characteristics of buprenorphine make exploration of 
outpatient use for treatment of NAS a ripe area for clinical research. 
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Table 1. Characteristics of Patients in the trial 
 
 
  Morphine Buprenorphine 
N  12 12 
Sex Male 4 6 
 Female 8 6 
Race White, non 
Hispanic 
11 12 
 African-
American 
1 0 
Birth weight (gm)  3010 2680 
Gestational Age 
(weeks) ║ 
 39.3 39.1 
Onset of 
Treatment. Mean 
Days after birth ║ 
 2.4 [SD 0.89] 2.3 [SD 1.4] 
1-Minute APGAR 
Score ║ 
 8.1 7.6 
5-Minute APGAR 
Score ║ 
 8.9 9.0 
Daily Maternal 
Methadone Dose 
(mg)  
 124 [SD 60] 157 [SD 57] 
║Mean  
Table 2 : Efficacy Outcomes of Buprenorphine and Neonatal Opium 
Solution Mean 
 
 Buprenorphine Morphine p value 
N 12 12  
Length of Treatment (days) 23 [SD 12] 38 [SD 14] 0.01 
Length of Stay (days) 32 [SD 24] 42 [SD 13] 0.05 
Phenobarbital adjunctive 
therapy (patients) 
3 1  
 
Table 3: Adverse Events 
Subject 
Allocation 
Number 
Treatment Adverse Event Serious 
AE 
Causality 
039 morphine oral thrush no unrelated 
paronychia of finger no unrelated 
reflux/poor feeding yes probably not 
related 
elevated 
transaminases 
no probably not 
related 
Cytomegalovirus 
infection 
no unrelated 
047 buprenorphine 
aminoaciduria no unrelated 
049 morphine conjunctivitis no unrelated 
050 morphine oral thrush no unrelated 
051 buprenorphine clavicle birth fracture no unrelated 
052 morphine reflux no unrelated 
 
Figure 1: Study Schema
Randomization 
Buprenorphine 15.9 mcg/kg in 3 
divided doses 
• Increase dose 25% until symptoms 
controlled 
• Phenobarbital added when dose 
reaches 60 mcg/kg/day 
Morphine 0.4 mg/kg/day in 6 divided 
doses 
• Increase dose 10% until symptoms 
controlled 
• Phenobarbital added when dose 
reaches 1 mg/kg/day 
Wean dose 10% per day as tolerated 
Screening 
 
Inclusion 
• >37 weeks gestation 
• In utero exposure to opioids 
• Need for pharmacologic therapy 
for NAS 
 
Exclusion 
• Exposure to benzodiazepines 
• Medical illness 
• Breastfeeding 
 
 
2 days observation prior to discharge 
Wean dose 10% per day as tolerated 
Cessation of therapy at 0.15 
mg/kg/day 
Cessation of therapy when within 
10% of initial dose 
Figure 2: Length of Treatment and Length of Stay 
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